Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24774067 | 0.81 | PSMB5 (0.33) | PSMB5ALDH1A1TDP1 | |
| SCHEMBL24004324 | 0.81 | ALDH1A1 (0.47) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL21955637 | 0.79 | PSMB5 (0.32) | PSMB5 | |
| SCHEMBL25132319 | 0.79 | PSMB5 (0.32) | PSMB5 | |
| SCHEMBL16920589 | 0.79 | PSMB5 (0.32) | PSMB5 | |
| SCHEMBL24307188 | 0.78 | ALDH1A1 (0.33) | PSMB5ALDH1A1LMNAMAPTPTGS2 | |
| SCHEMBL20698861 | 0.78 | ALDH1A1 (0.48) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL15980869 | 0.78 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL15502266 | 0.77 | KDM4E (0.31) | — | |
| SCHEMBL7749779 | 0.77 | DPP4 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | RCC2, REN, VHL | PSMB5 1658/4885ALDH1A1 3602/4885LMNA 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.